2 results
Approved WMOCompleted
Primary: to assess the efficacy of ambrisentan 5mg after treatment period of 16 weeks, in subjects with inoperable CTEPH. Secondary: safety and tolerability.
Approved WMOCompleted
Primary Objective: a reduction in bronchoconstriction, measured by auto-PEEP, in patients with AE-COPD. Secondary Objective(s): * To test for a dose-dependency. * Decrease in pulmonary artery pressures* Enhance cardiac output* Measure occurrence of…